RBC Capital Maintains Outperform Rating on Revolution Medicines, Sets $260 Target
RBC Capital maintained its Outperform rating on Revolution Medicines and a $260 price target. The target implies 38.0% upside from the Oct. 13 close of $188.44.
RBC Capital maintained its Outperform rating on Revolution Medicines and a $260 price target. The target implies 38.0% upside from the Oct. 13 close of $188.44.